KRAS and colorectal neoplasm: Similarly, colorectal tumours that are treated with anti-EGFR antibodies develop resistance through three main mechanisms: mutations in the antibody-binding site (such as the EGFR ECD variants)10, 11; activation of alternative pathways28, 29; or reactivation of downstream signalling (such as KRAS or NRAS mutations)30.